BioSpace News Archive

Plex Pharmaceuticals, Inc., announced that it has been awarded two Small Business Innovation Research grants from the National Institutes of Health National Eye Institute: a $1.3 million Phase II grant and a $300,000 Phase I grant.

RGX-111 and RGX-121 continue to be well-tolerated in patients with MPS I and MPS II following one-time intracisternal administration

Concert Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration granted Breakthrough Therapy Designation for the Company’s oral Janus kinase inhibitor, CTP-543, for the treatment of adult patients with moderate-to-severe alopecia areata.

Foghorn® Therapeutics Inc., a company advancing an unprecedented class of therapeutics targeting the chromatin regulatory system in oncology, announced that it has entered into a strategic collaboration with Merck, known as MSD outside the United States and Canada.

Talaris Therapeutics, Inc. announced that the U.S. Food and Drug Administration has approved the company’s Investigational New Drug application for the evaluation of Talaris’ novel cell therapy FCR001 in the treatment of diffuse systemic sclerosis, a severe form of the rare autoimmune disease scleroderma.

Mevion Medical Systems announced that patient treatment has commenced on the MEVION S250i Proton Therapy System® at the S. Lee Kling Proton Therapy Center at Siteman Cancer Center, based at Washington University School of Medicine and Barnes-Jewish Hospital in St. Louis.

AVROBIO, Inc. announced that the company has granted non-statutory stock options for the purchase of up to an aggregate of 138,200 shares of the company’s common stock to five new employees as inducement awards under the company’s 2019 Inducement Plan, in accordance with Nasdaq Listing Rule 5635.

PharmaCyte Biotech, Inc., a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced that it has successfully completed the three-month product stability testing that is required by the U.S. Food and Drug Administration for its CypCaps™ and CypCaps™ passed all of the FDA-required tests.

Sanofi Canada is pleased to announce that Health Canada has approved SARCLISA™ in combination with pomalidomide and dexamethasone for the treatment of adults with relapsed and refractory multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.2

Eikonizo Therapeutics, Inc., a biotechnology company developing novel, first-in-class brain-penetrant HDAC6 inhibitors to slow or stop progression of neurodegenerative disorders, has published results from the First-in-Human Study of [18F]EKZ-001 in healthy volunteers in the European Journal of Nuclear Medicine and Molecular Imaging.